Rifampin and trimethoprim were used alone and in combination in the treatment of chronic osteomyelitis due to Staphylococcus aureus in rabbits. Rifampin levels in infected bone were well above the miniimum inhibitory concentration for the infecting strain of S. aureus for at least 4 h after injection. In contrast, trimethoprim levels in diseased bone were below the minimum inhibitory concentration as early as 1 h after injection. Trimethoprim or rifampin, administered alone for 14 days, were ineffective in sterilizing infected rabbit bones. The combination of rifampin plus trimethoprim was significantly more effective (P < 0.005) than either agents given alone for a comparable duration of time. Staphylococci isolated from the bones of rabbits treated with rifampin alone or rifampin plus trimethoprim were uniformly resistant to rifampin, but retained their susceptibility to trimethoprim.
Previous studies in an experimental model of staphylococcal osteomyelitis have shown that the use of single agents such as lincomycin, cephalothin, gentamicin, oxacillin, and rifampin was only moderately effective in sterilizing bone (7) . More recent studies, in the same model, showed that combinations of oxacillin plus sisomicin or rifampin combined with an aminoglycoside or cephalothin were significantly more effective (7, 8) .
One of the problems in the treatment of chronic osteomyelitis has been the need to administer antibiotics parenterally over a prolonged period. A major attraction of the use of rifampin is that the drug can be administered orally once or twice a day and that levels are attained in serum which should be high enough to maintain adequate levels in bone (11) . However, because of the development of rifampinresistant colonies, this agent cannot be recommended for use by itself. Trimethoprim, which can also be administered orally and which has activity against Staphylococcus aureus, was therefore tested as an antimicrobial agent to be used in combination with rifampin.
MATERIALS AND METHODS Production of osteomyelitis. The technique for production of osteomyelitis has been described previously (6) . New Zealand white rabbits (weight, 4 lb; ca. 1.8 kg) received an intramedullary injection into the tibia of sodium morrhuate and 3 x 10' colony-forming units of S. aureus (6) . This strain of S. aureus is resistant to penicillin, erythromycin, and tetracycline and susceptible to oxacillin, cephalothin, gentamicin, rifampin, and trimethoprim.
Culture of bone. Cultures were obtained by techniques described previously (9) .
Measurement ofantibiotics in serum and bone. The cylinder plate method was used for the assay of antibiotics (4) .
Serum assay. Rifampin (kindly supplied by John Eble, Dow Chemical Corp., Indianapolis, Ind.) was assayed as described previously (7); the minimum quantity of rifampin that could be measured was 0.1 pg/ml. For trimethoprim assay, standard curves were (0.025 IU of enzyme per ml). The trimethoprim powder was dissolved in 0.5 N lactic acid. All sera and standards were further diluted in 50% normal rabbit serum and 50% 0.1 M phosphate buffer at pH 7.3. The minimum quantity of trimethoprim that could be measured was 0.01 g/ml.
Bone assay. The bones were prepared as described previously (7) . The minimum quantities of trimethoprim and rifampin that could be measured were 0.01 and 0.1 ug/ml of bone suspension, respectively; the amount of antibiotic was expressed as micrograms per gram of bone.
To determine whether trimethoprim or rifampin binds to bone powder, standards of each antibiotic were agitated for 4 h before assay either with suspensions of bone powder from uninfected rabbits or with buffer. No differences in zone sizes were seen, indicating that the antibiotics did not bind to bone powder in this assay. (2) . The level of trimethoprim attained in bone in humans is not known; in rabbits, the bone level was approximately 13% of simultaneous serum levels, a ratio which approximates that for rifampin and sisomicin. Despite the relatively good penetration into bone, because of the high MIC of our organism (1.25 ug/ml), the levels of trimethoprim in bone in rabbits did not equal or exceed the MIC at any time after injection. It is conceivable that trimethoprim might have been more effective if tested against a strain of S. aureus that required a lower MIC or if the drug were given in higher dosage or more frequently.
The in vitro results of combining trimethoprim and rifampin indicated antagonism by checkerboard technique and no enhancement of killing in time-kill curves. Others have also reported antagonism between these two agents in in vitro testing (5) ; the interpretation of these results has been disputed by other workers (1, 10) . In the therapeutic trials, the combination of rifampin and trimethoprim was significantly more effective than either agent alone. Since the presumed reason for this therapeutic success was the fact that trimethoprim is acting to inhibit or kill rifampin-resistant mutants, it is likely that any antibiotic that is effective against the infecting bacteria could serve this purpose.
The combination of rifampin and trimethoprim was approximately as effective as the previously tested combinations of rifampin plus sisomicin or rifamnpin plus cephalothin (7) . The only regimen previously tested that was significantly more effective than rifampin plus trimethoprim was the combination of three agents (rifampin, cephalothin, and sisomicin) (7) .
In summary, the combination of rifampin plus trimethoprim (despite the theoretical disadvantages of using trimethoprim against an organism with relatively high resistance) was effective in the treatment of staphylococcal osteomyelitis in rabbits. The potential attractiveness of such a combination of antibiotics is that both can be administered orally; oral administration, if therapeutically effective, would allow for shorter periods of hospitalization and reduced costs.
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Based on the animals studied, there is nothing to recommend the combination of rifampin and trimethoprim over the combination of rifampin plus cephalothin or sisomicin. Since the peak serum level of trimethoprim in humans after an oral dose of 160 mg is approximately 2 ,ug/ml (3), it is likely that the level in bone, with orally administered trimethoprim, will be below the MIC for many strains of staphylococci; this fact makes the combination of rifampin and trimethoprim theoretically less attractive for use as treatment for chronic staphylococcal osteomyelitis. Whether these experimental results and theoretical considerations can be extrapolated to the clinical situation in humans awaits controlled trials.
